Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • adapt

    - PMLiVE

    Mission Therapeutics advances Parkinson’s disease candidate

    The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

    - PMLiVE

    Lilly and WHO Foundation partner to support global dementia action plan

    The partnership will provide financial support and strengthen early detection and intervention efforts

    - PMLiVE

    Lilly launches global Alzheimer’s campaign with Julianne Moore

    The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

    - PMLiVE

    PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

    The US-based company develops light-based therapies for neurodegenerative conditions

    - PMLiVE

    GSK to explore link between Shingrix and dementia risk in new UK research collaboration

    More than 55 million people worldwide are currently living with the neurodegenerative disease

    - PMLiVE

    UK drug repurposing study identifies several potential dementia treatments

    An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

    - PMLiVE

    GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

    The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

    - PMLiVE

    Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

    The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

    - PMLiVE

    Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

    Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

    - PMLiVE

    Lancet Commission report identifies two new modifiable dementia risk factors

    The new risk factors identified are untreated vision loss and high low-density lipoprotein

    - PMLiVE

    Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

    Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

    - PMLiVE

    NHS figures reveal record number of people in England being diagnosed with dementia

    Around a third of people living with dementia in England have not received a diagnosis

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links